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Abstract. 
 
How Bcl-2 and its pro-survival relatives pre-
vent activation of the caspases that mediate apoptosis is 
unknown, but they appear to act through the caspase 
activator apoptosis protease–activating factor 1 (Apaf-
1). According to the apoptosome model, the Bcl-2–like 
proteins preclude Apaf-1 activity by sequestering the 
protein. To explore Apaf-1 function and to test this 
model, we generated monoclonal antibodies to Apaf-1 
and used them to determine its localization within di-
verse cells by subcellular fractionation and confocal la-
ser scanning microscopy. Whereas Bcl-2 and Bcl-x
 
L
 
 
were prominent on organelle membranes, endogenous 
Apaf-1 was cytosolic and did not colocalize with them, 
even when these pro-survival proteins were overex-
pressed or after apoptosis was induced. Immunogold 
electron microscopy conﬁrmed that Apaf-1 was dis-
persed in the cytoplasm and not on mitochondria or 
other organelles. After the death stimuli, Bcl-2 and
Bcl-x
 
L
 
 precluded the release of the Apaf-1 cofactor cy-
tochrome
 
 c 
 
from mitochondria and the formation of 
larger Apaf-1 complexes, which are steps that presage 
apoptosis. However, neither Bcl-2 nor Bcl-x
 
L
 
 could pre-
vent the in vitro activation of Apaf-1 induced by the ad-
dition of exogenous cytochrome
 
 c
 
. Hence, rather than 
sequestering Apaf-1 as proposed by the apoptosome 
model, Bcl-2–like proteins probably regulate Apaf-1 in-
directly by controlling upstream events critical for its 
activation.
Key words: caspases • cell death • Bcl-2 • mitochon-
dria • subcellular localization
 
Introduction
 
The evolutionarily conserved process of apoptosis is criti-
cal both to remove unwanted cells during development
and to maintain tissue homeostasis, and its disregulation
can engender many diseases (Thompson, 1995; Strasser
et al., 1997; Vaux and Korsmeyer, 1999). Apoptosis is
launched when critical initiator cysteine proteases (cas-
pases) are processed into active enzymes, which then ini-
tiate a proteolytic cascade by activating downstream cas-
pases such as caspase-3 (Thornberry and Lazebnik, 1998).
The processing of the apical caspases requires adapter
molecules such as Apaf-1 (Li et al., 1997; Zou et al., 1997).
In the presence of its cofactors, dATP and cytochrome
 
 c
 
,
Apaf-1 promotes the autocatalytic activation of caspase-9
(Li et al., 1997; Zou et al., 1997; Srinivasula et al., 1998),
triggering one major pathway to apoptosis (Hakem et al.,
1998; Kuida et al., 1998).
The Bcl-2 family of proteins is a critical upstream regu-
lators of apoptosis (Adams and Cory, 1998; Gross et al.,
1999). Apoptosis protease–activating factor 1 (Apaf-1)
 
1
 
probably is a crucial target for its pro-survival members
because Apaf-1–deficient cells are refractory to several cy-
totoxic signals that are inhibitable by Bcl-2 (Cecconi et al.,
1998; Yoshida et al., 1998). However, whether Bcl-2 and
its close relatives control Apaf-1 activity directly remains a
central unresolved issue (Adams and Cory, 1998; Green
and Reed, 1998; Gross et al., 1999).
In the widely discussed apoptosome model (Hengartner,
1997), first proposed for the nematode 
 
Caenorhabditis ele-
gans
 
, the Bcl-2–like proteins directly sequester Apaf-1.
Developmental cell death in the worm requires both the
Apaf-1 homologue cell death abnormal (CED) 4 and the
caspase CED-3, but can be prevented by the Bcl-2 homo-
logue CED-9 (Ellis et al., 1991). Biochemical studies in
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heterologous overexpression systems suggested that CED-9
sequesters CED-4 and CED-3 (Chinnaiyan et al., 1997;
Spector et al., 1997; Wu et al., 1997a,b). For example,
CED-9, which localized to the intracellular membranes of
mammalian and yeast cells, caused coexpressed CED-4 to
translocate from the cytosol to those sites, suggesting that
the putative CED-9/CED-4/CED-3 apoptosome complex
resides on organelles (James, 1997; Wu et al., 1997b).
The conservation of the apoptotic pathway would argue
for analogous mammalian apoptosomes involving Apaf-1,
but coimmunoprecipitation experiments have yielded con-
flicting data. Overexpressed Apaf-1 was reported to asso-
ciate with the pro-survival proteins Bcl-x
 
L 
 
(Hu et al., 1998;
Pan et al., 1998), Bcl-2 (Fang et al., 1998), and Boo/Diva
(Inohara et al., 1998; Song et al., 1999). A recent study
from this laboratory, however, found no evidence for
coimmunoprecipitation of any of the known mammalian
pro-survival proteins with Apaf-1 (Moriishi et al., 1999).
As the coimmunoprecipitation data have given conflict-
ing results, it is important to test the apoptosome model
in alternative ways. The model strongly predicts that most,
if not all, Apaf-1 molecules will be found at the sites
where pro-survival molecules like Bcl-2 and Bcl-x
 
L
 
 reside,
namely on the cytoplasmic aspect of the mitochondrion,
the nuclear envelope, and the ER (Monaghan et al., 1992;
Krajewski et al., 1993; Gonzalez-Garcia et al., 1994; Lith-
gow et al., 1994). Although Apaf-1 was originally isolated
from the soluble fraction of HeLa cells (Zou et al., 1997)
and was recently reported to behave as a soluble protein
on subcellular fractionation (Zhivotovsky et al., 1999), its
localization inside cells has not been definitively estab-
lished. Therefore, to investigate how Apaf-1 might be reg-
ulated and to test the apoptosome model, we have gener-
ated mAbs to Apaf-1, and used them to locate the
endogenous protein in diverse cell types. The subcellular
fractionation and microscopic studies (confocal and elec-
tron microscopy) reported here indicate that Apaf-1 is a
soluble protein with a cytoplasmic localization distinct
from that of pro-survival proteins such as Bcl-2 and Bcl-x
 
L
 
.
Moreover, its location did not alter in response to apop-
totic stimuli. These findings indicate that, contrary to the
apoptosome model, Bcl-2–like proteins do not directly se-
quester Apaf-1 and, instead, must regulate its activity by
the control of upstream events.
 
Materials and Methods
 
Monoclonal Rat Anti–Apaf-1 Antibodies
 
Monoclonal rat anti–Apaf-1 antibodies were generated and selected ac-
cording to a previous protocol (O’Reilly et al., 1998). In brief, Wistar rats
were immunized with purified bacterial recombinant human Apaf-1 pro-
tein (residues 1–464: caspase recruitment domain [CARD] plus CED-4
homology regions). The hybridoma clones, resulting from a fusion of the
spleen cells with Sp2/0 myeloma cells, were screened by flow cytometric
analysis for immunofluorescent staining of 293T cells transfected with a
plasmid encoding COOH terminally hemagglutinin (HA)-tagged full-
length human Apaf-1 (Moriishi et al., 1999). The lines were cloned twice
and the antibodies were purified on protein G–Sepharose columns (Am-
ersham Pharmacia).
 
Cell Culture, Transfection, Induction of Cell Death and 
Expression Constructs
 
All cell lines were cultured in the high glucose version of DME medium
 
supplemented with 13 
 
m
 
M folic acid, 250 
 
m
 
M 
 
L
 
-asparagine, 50 
 
m
 
M 2-mer-
captoethanol, and 10% FCS. Human T lymphoblasts were isolated and ac-
tivated as described (James, 1997). 293T, COS-7, or HeLa cells were tran-
siently transfected using Lipofectamine (Life Technologies; Huang et al.,
1997b) and analyzed the next day. To generate HeLa lines that stably
overexpress Bcl-2 or Bcl-x
 
L
 
, cells transfected with vectors that also express
the puromycin resistance gene were plated at a limiting dilution in the
presence of 1 
 
m
 
g ml
 
2
 
1
 
 puromycin (Sigma Chemical Co.). Clones express-
ing the relevant protein were identified by flow cytometric analysis
(Huang et al., 1997a). Cell death was induced by treating cells with 1 nM–
1 
 
m
 
M staurosporine (Sigma Chemical Co.), 0.1–1.0 
 
m
 
g ml
 
2
 
1
 
 etoposide
(VP-16; Della West), or by UV irradiation (HeLa cells 10–100 J m
 
2
 
2
 
;
HepG2 cells at 800 J m
 
2
 
2
 
). Cell viability was determined by counting cells
stained with vital dye (0.4% eosin) in a hemacytometer or by flow cytomet-
ric analysis of propidium iodide (5 
 
m
 
g ml
 
2
 
1
 
; Sigma Chemical Co.)–stained
cells. The expression constructs for human Apaf-1, human Bcl-2, and hu-
man Bcl-x
 
L
 
 have been described (Huang et al., 1997a; Moriishi et al., 1999).
 
Subcellular Fractionation, Sucrose Gradients, 
Immunoprecipitation, and Immunoblotting
 
To prepare total cell extracts, cells were harvested in lysis buffer (20 mM
Tris-HCl, pH 7.4, 135 mM NaCl, 1% Triton X-100, and 10% glycerol),
supplemented with 0.5 
 
m
 
g ml
 
2
 
1
 
 Pefabloc, 100 
 
m
 
g ml
 
2
 
1
 
 soybean trypsin in-
hibitor, and 1 
 
m
 
g ml
 
2
 
1
 
 each of leupeptin, aprotinin, and pepstatin (Sigma
Chemical Co. or Roche). To separate the cytosolic fraction from other
cellular components (Ramsby et al., 1994), cells were permeabilized in
0.025% digitonin (Calbiochem-Novabiochem Corp.) dissolved in
HMKEE buffer (20 mM Hepes, pH 7.2, 5 mM MgCl
 
2
 
, 10 mM KCl, 1 mM
EDTA, and 1 mM EGTA and protease inhibitors) containing 250 mM su-
crose. The organelles, cytoskeleton, and membranes were pelleted by cen-
trifugation (13,000 rpm for 2 min at 4
 
8
 
C). The supernatant (cytosol; s) was
carefully removed and the pellet (p) was solubilized in RIPA buffer (150
mM NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS, 50 mM
Tris-HCl, pH 8.0, and protease inhibitors). Protein content was deter-
mined by the Bradford reaction (Bio-Rad), and equivalent portions of
each fraction was used for further analysis.
For sedimentation experiments, cells were resuspended in HMKEE
buffer containing 250 mM sucrose, allowed to swell on ice for 10 min, and
lysed using a Dounce homogenizer (100 strokes with a type B pestle;
Konte Glassware Corp.). After centrifugation at 900 
 
g
 
 for 5 min at 4
 
8
 
C to
remove unlysed cells, nuclei, and cell debris, the supernatant was loaded
on a continuous 10–50% sucrose gradient in HMKEE buffer, centrifuged
(40,000 rpm for 20 h at 4
 
8
 
C) in an SW40 Ti rotor (Beckman Instruments,
Inc.), and the fractions were manually collected. The broad spectrum
caspase inhibitor zVAD.fmk (Z-Val-Ala-DL-Asp-fluoromethylketone;
Bachem Bioscience Inc.) was used at 50 
 
m
 
M.
Immunoprecipitations were performed as described (Moriishi et al.,
1999). Total cell lysates, immunoprecipitates, or fractionated samples
were resolved by SDS-PAGE (Novex) and electroblotted onto nitrocellu-
lose membranes (Amersham Pharmacia). Nonspecific binding was
blocked by incubating the filters in PBS containing 5% skimmed milk (Di-
ploma), 1% casein (Sigma Chemical Co.), and 0.1% Tween 20 (Sigma
Chemical Co.) for 
 
$
 
1 h before incubation with the antibody. Mouse
mAbs included anti-HA 16B12 (HA.11; BAbCO), anti-HSP60 and anti-
HSP90 (both from Stressgen), antiporin/VDAC (Calbiochem-Nova-
biochem Corp.), anti-human Bcl-2 (Bcl-2-100), anti–Bcl-x (7B2.5; a gift
from C. Thompson, University of Pennsylvania, Philadelphia, PA), anti-
Golgi 58-kD protein (58K-9; Sigma Chemical Co.), anti–cytochrome
 
 c
 
(7H8.2C1; PharMingen), and anti–caspase-9 (2-22; a gift from Y. Lazeb-
nik, Cold Spring Harbor Laboratory, NY). Rabbit polyclonal antibodies
were anticalnexin (Stressgen), anti–Bcl-x, and anti–caspase-9 (both from
PharMingen). Bound antibodies were detected with HRP-conjugated
secondary reagents (Silenus or Southern Biotechnology Associates Inc.)
and enhanced chemiluminescence (Amersham Pharmacia). Blots were
stripped and reprobed according to manufacturer’s instructions (Amer-
sham Pharmacia).
 
Immunofluorescence Staining and Confocal Microscopy
 
To stain for Apaf-1, cells were grown on glass coverslips (10-mm diam;
Lomb Scientific) or in chamber slides (Becton Dickinson & Co.). Nonad-
herent cells or cells treated with apoptotic stimuli were attached using
poly-
 
L
 
-lysine or Cell TAK (Becton Dickinson & Co.), fixed with 50% ace-
tone/50% methanol for 10 min at room temperature, and permeabilized 
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with 0.5% Tween 20. COS cells transiently expressing Apaf-1 HA were in-
cubated overnight at 4
 
8
 
C with the primary antibodies (mouse anti-HA and
rat anti–Apaf-1), washed with 0.2% Tween 20 in PBS, and incubated with
FITC-conjugated goat anti–mouse Ig (Southern Biotechnology Associates
Inc.) and rhodamine-conjugated goat anti–rat Ig (Jackson ImmunoRe-
search Laboratories, Inc.). Finally, the slides were mounted in fluorescent
mounting medium (DAKO). Controls included staining with primary or
secondary antibody alone and staining of untransfected cells. To stain for
mitochondria, cells were incubated at 37
 
8
 
C for 15 min with 500 nM Mi-
toTracker red, and for lysosomal staining, with LysoTracker red for 3 h
(both from Molecular Probes).
Detection of endogenous Apaf-1 required amplification of the immu-
nofluorescence signal by tyramide signal amplification (NEN), which uses
HRP to catalyze the deposition of biotin-labeled tyramide (Bobrow et al.,
1992). Endogenous peroxidase activity was quenched by incubation in 3%
H
 
2
 
O
 
2
 
, 10% methanol for 15 min, and cells were permeabilized in 0.5%
Tween 20 in PBS for 15 min at room temperature. Apaf-1
 
 
 
was detected by
incubation with mAbs 2E12 or 19G9 overnight at 4
 
8
 
C, followed by 30 min
with HRP-conjugated goat anti–rat IgG (Southern Biotechnology Associ-
ates Inc.). After tyramide amplification for 7 min (with mAb 2E12) or 3.5
min (with 19G9), the staining was revealed with FITC- or Texas red–con-
jugated streptavidin (Caltag or GIBCO BRL). Between steps, the slides
were washed three times in PBS containing 1% BSA and 0.1% Tween 20.
Other antigens were detected by incubation with an appropriate primary
antibody overnight at 4
 
8
 
C and an FITC-conjugated secondary reagent for
1 h (Southern Biotechnology Associates Inc.). Controls included staining
with an isotype-matched antibody (anti-rat IgG2a 
 
k
 
 R35-95; PharMingen)
or staining with secondary reagents alone. Samples were analyzed with a
Leica confocal laser scanning microscope using SCANware software
(Leica Lasertechnik).
 
Immunogold Electron Microscopy
 
Healthy or UV-irradiated HepG2 cells were fixed for 2 h in 4% paraform-
aldehyde, 0.1% glutaraldehyde, 4% sucrose in Hepes-buffered saline, pH
7.4 (150 mM NaCl, 50 mM Hepes, 4 mM MgCl
 
2
 
, 4 mM CaCl
 
2
 
, and 2 mM
KCl). After several washes with PBS, the cells were scraped off the dishes,
gently pelleted, and resuspended in 0.1 M Na
 
3
 
PO
 
4
 
, pH 7.4, containing
10% gelatin. The pellets were cooled on ice until solid, and smaller cubes
were cryoprotected in 15% polyvinyl-pyrrolidone and 1.7 M sucrose. The
infused blocks were hardened in liquid nitrogen before cryosectioning at
 
2
 
100
 
8
 
C using a Diatome diamond knife on a Reichert FCS/Ultracut S.
The ultra-thin sections were collected onto Formvar-coated nickel grids in
1% methylcellulose, and 1.15 M sucrose and stored at 4
 
8
 
C (Kleijmeer et
al., 1997). The grids were floated on 2% gelatin in 0.1 M Na
 
3
 
PO
 
4
 
 for 30
min. Aldehyde groups and nonspecific binding were blocked by incubat-
ing the samples first in 50 mM glycine in PBS, and then in incubation
buffer (10 mM Na
 
3
 
PO
 
4
 
, 0.1% cold fresh water fish gelatin, 0.5% ovalbu-
min, 150 mM NaCl, 20 mM NaN
 
3
 
) containing 5% normal goat serum. The
samples were incubated with 2 
 
m
 
g ml
 
2
 
1
 
 anti–Apaf-1 2E12 or rat IgG2a 
 
k
 
R35-95 in IB, washed in IB, and then treated with the secondary antibody
(10 nM gold-conjugated goat anti–rat IgG; British Biocell) diluted 1:40 in
IB. After extensive washing, the samples were fixed for 5 min in the fixa-
tive above, washed extensively with Milli-Q water, and contrasted in
1.71% methylcellulose, 0.43% uranyl acetate (Kleijmeer et al., 1997). The
sections were examined at 80 kV using a JEOL 1200EX transmission elec-
tron microscope. All chemicals were obtained from Sigma Chemical Co.
 
Software Applications
 
Immunoblots and immunogold EM images were scanned using a AGFA
SNAPScan 1236 scanner and FotoLook SA 2.09.6 software. These and the
confocal scanning images were edited by using Adobe Photoshop or Free-
Hand software.
 
Results
 
Novel Monoclonal Anti–Apaf-1 Antibodies
 
To generate mAbs against human Apaf-1, myeloma cells
were fused with spleen cells from rats immunized with
truncated human Apaf-1 recombinant protein containing
the NH
 
2
 
-terminal CARD and CED-4 homologous regions
(Zou et al., 1997). Clones secreting antibodies specific for
Apaf-1 were identified by a rapid flow cytometric screen
designed to select antibodies that recognize the native pro-
tein (O’Reilly et al., 1998; see Materials and Methods).
Two clones of independent origin, 2E12 and 19G9, yielded
mAbs suitable for various applications (Fig. 1).
The 2E12 mAb proved to be specific for the human pro-
tein. On immunoblots, it recognized a single 130-kD pro-
tein in human epithelial cells (293T, HeLa, MCF-7, and
Figure 1. Characterization of anti–Apaf-1 mAbs. (A) Immuno-
blots with mAb 2E12 revealing endogenous Apaf-1. Lysates from
106 HeLa, MCF-7, 293T, COS, Jurkat, and activated primary hu-
man T cells, and 105 untransfected 293T cells or those transiently
transfected with an Apaf-1 HA construct, were resolved by SDS-
PAGE, and the membrane was probed with anti–Apaf-1 2E12
(left panel) or anti-HA (right panel). The asterisk indicates an
NH2-terminal cleavage product commonly seen in cells overex-
pressing Apaf-1. (B) Confocal microscopy showing the compara-
ble staining of Apaf-1 HA by anti–Apaf-1 and anti-HA. Untrans-
fected COS cells were stained with Apaf-1 mAb 2E12 and
rhodamine-conjugated anti-rat IgG (first panel). COS cells tran-
siently expressing Apaf-1 HA were similarly stained (second
panel) and with anti-HA antibody plus FITC-conjugated anti-
mouse IgG (third panel). In the superimposed images (fourth
panel), yellow indicates regions of costaining. The images are
representative of $20 cells examined. (C) Properties of 2E12 and
19G9, including applicability for immunofluorescence staining
(IF), immunohistochemical staining (IH), immunoprecipitation
(IP), and Western blotting (WB). Whereas 2E12 mAb recognizes
only the human protein (hs), 19G9 mAB also recognizes monkey
(ca), mouse (mm), and rat (rn) Apaf-1. Bars, 10 mm. 
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HepG2) and human hematopoietic cells (Jurkat, SKW6,
CEM, and primary human lymphoblasts) but not in the
monkey kidney epithelial COS cell line (Fig. 1 A and data
not shown). The size of the endogenous protein was com-
parable to that of HA-tagged Apaf-1 transiently expressed
in the 293T cells, though the overexpressed protein also
yielded an 
 
z
 
60-kD NH
 
2
 
-terminal proteolytic fragment
(Fig. 1 A). In confirmation of the specificity of the anti-
bodies, their staining pattern on COS cells expressing hu-
man Apaf-1 HA was identical to the staining with anti-HA
antibody (Fig. 1 B). Labeling was negligible with an iso-
type-matched control antibody or with secondary reagents
alone (data not shown) and in untransfected COS cells
stained with mAb 2E12 (Fig. 1 B). The 2E12 mAb also
proved useful for immunoprecipitation and immunofluo-
rescence, whereas 19G9, which recognizes Apaf-1 from
several species, worked in all applications tested except for
immunoblotting (Fig. 1 C). The 2E12 epitope mapped to
the NH
 
2
 
-terminal CARD (residues 1–97), and the 19G9
epitope mapped to the CED-4 homology region (within
residues 140–412; data not shown). Most subsequent ex-
periments were performed using 2E12 and, where appro-
priate, confirmed with 19G9.
 
Apaf-1 Has a Cytoplasmic Localization Distinct from 
Bcl-2 and Bcl-x
 
L
 
Our initial confocal microscopy studies of transiently
transfected 293T, HeLa, or MDCK cells showed HA- or
GFP-tagged Apaf-1 to be cytoplasmic (Fig. 1 B). We sub-
sequently focused on the endogenous protein to preclude
artifacts of overexpression, such as the proteolytic cleav-
age seen in Fig. 1 A or nonspecific aggregation (Johnston
et al., 1998). Because of its low abundance (an estimated
5,000–8,000 molecules per epithelial cell; data not shown),
detection of endogenous Apaf-1 with either antibody re-
quired tyramide signal amplification (Bobrow et al., 1992;
see Materials and Methods).
In all cell types examined, endogenous Apaf-1 exhibited
a granular cytoplasmic distribution (Fig. 2). In the HeLa
cervical carcinoma cell line, which was not stained by a
control antibody or the secondary reagents (data not
shown), both the 2E12 antibody (Fig. 2 A) and 19G9 (data
not shown) revealed Apaf-1 distributed throughout the cy-
toplasm, irrespective of the fixative used (paraformalde-
hyde or acetone/methanol). There was no localization to
the nuclear membrane, nor any substantial overlap with
the mitochondria stained with MitoTracker red (Fig. 2 A,
bottom). The limited apparent costaining of Apaf-1 and
MitoTracker red near the nucleus probably reflect incom-
plete separation of the intense signals generated, and the
inadequate lateral resolution of bright signals generated
by two adjacent objects, recognized limitations of confocal
laser scanning microscopy (Carlsson, 1991; Brelje et al.,
1993). To confirm that the Apaf-1 pattern differed from
that of mitochondria, we compared its staining, in human
Figure 2. Confocal images showing Apaf-1 localized to the cytoplasm but not significantly to the mitochondria of epithelial cells. Stain-
ing for endogenous Apaf-1 in HeLa (A), MCF-7 (B), or HepG2 (C) cells with anti–Apaf-1 2E12 revealed by FITC-conjugated secondary
reagents (top) and for mitochondria with MitoTracker red (middle). HepG2 cells were also stained with anti-HSP60 (plus FITC-conju-
gated anti-mouse IgG) and either Texas red–conjugated detection of anti–Apaf-1 2E12 (D) or MitoTracker red (E). In the overlaid im-
ages (bottom), yellow staining indicates potential colocalization. All data are representative of $20 cells examined. Bars, 10 mm. 
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HepG2 hepatoblastoma cells, with that of the known mito-
chondrial protein HSP60. Whereas staining of HSP60 co-
incided precisely with Mitotracker red (Fig. 2 E), most of
the Apaf-1 appeared distinct from mitochondria, as re-
vealed by costaining with either MitoTracker red (Fig. 2 C)
or for HSP60 (Fig. 2 D). Apaf-1 had a similar cytoplasmic
distribution, distinct from that of mitochondria in the
MCF-7 human breast carcinoma cell line (Fig. 2 B) as well
as fibroblasts (NIH3T3, Rat-1A) and lymphocytes (Jurkat
human T-lymphoma, activated primary human T cells;
data not shown). Apaf-1 also failed to colocalize with
markers for the Golgi apparatus (Golgi p58) or lysosomes
(LysoTracker; data not shown).
The Apaf-1 confocal pattern still might conceivably re-
flect its association with an organelle. Alternatively, as
only a few hundred Apaf-1 molecules would be expected
in any optical plane, the staining might simply reflect the
amplified signals from individual or small clusters of Apaf-1
molecules. To distinguish between these two possibilities
and further refine its localization, we used immunogold-
labeled antibodies in an electron microscopic analysis of
HepG2 hepatocytes. No staining at all was observed with
an isotype-matched control antibody (data not shown).
Examination of over fifty fields in multiple independent
preparations, however, revealed Apaf-1 molecules scat-
tered sparsely throughout the cytoplasm but not within the
nuclei (Fig. 3). The vast majority appeared as single iso-
lated particles, and almost none were in contact with an in-
tracytoplasmic membrane. Importantly, the numerous
mitochondria present in these liver cells exhibited no sig-
nificant Apaf-1 staining (Fig. 3), and identical results were
obtained with HeLa cells (data not shown). Thus, in di-
 
verse cell types, Apaf-1 did not localize to the nuclear en-
velope, mitochondria, and the ER, which are the major
sites where Bcl-2 resides (see also below). Instead, Apaf-1
is located diffusely throughout the cytoplasm.
 
Apaf-1 Is a Soluble Protein, Not Associated with Bcl-2, 
Bcl-x
 
L
 
, or Procaspase-9
 
It is important to establish the Apaf-1 localization using
different fractionation techniques, because some can gen-
erate artifacts (Hsu and Youle, 1997). To confirm that
Apaf-1 was cytosolic, HeLa cells were lysed with 0.025%
digitonin, which permeabilizes only the plasma mem-
brane, and the lysates were centrifuged to generate a cyto-
solic fraction (s) and a pellet (p) containing the organelles,
membranes, and cytoskeleton (Ramsby et al., 1994). Im-
munoblotting (Fig. 4 A) revealed Apaf-1 almost exclu-
sively in the cytosolic fraction, whereas markers for the
mitochondria (VDAC/porin) or the ER (calnexin) were
confined to the pellet. The outer mitochondrial membrane
clearly remained intact because the intermembrane pro-
teins cytochrome
 
 c 
 
(see Fig. 6) and HSP60 (data not shown)
were confined to the pellet fraction. As expected (Lithgow
et al., 1994), Bcl-2 appeared only in the insoluble frac-
tion. As in another fractionation technique (Hsu et al.,
1997), Bcl-x
 
L
 
 resided in both fractions, possibly reflecting
a weaker interaction with intracytoplasmic membranes.
Apaf-1 was also exclusively cytosolic in MCF-7 (Fig. 4 B),
Jurkat (Fig. 4 C), HepG2 (Fig. 4 D), 293T, and activated
primary human T cells (data not shown).
In case detergents had altered Apaf-1 behavior, we also
prepared HeLa cell lysates by Dounce homogenization,
Figure 3. Diffuse cytoplasmic localization of endogenous Apaf-1 revealed by immunogold electron microscopy. HepG2 cells prepared
by cryosectioning were immunolabeled using anti–Apaf-1 2E12 and 10 nM gold-conjugated goat anti–rat IgG antibody. The extracellu-
lar matrix (E), a representative nuclear section (N), lipid-containing vacuoles (L), mitochondria (M), and some of the gold particles (ar-
rows) are indicated. 
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centrifuged them on sucrose gradients, and analyzed the
fractions by immunoblotting (Fig. 4 E). Whereas organelle
markers such as VDAC/porin and calnexin appeared in
the denser fractions, Apaf-1 behaved like a free mono-
meric protein of 130 kD (Zou et al., 1999). In contrast,
Bcl-2 tracked with the organelle markers. Consistent with
the results above, Bcl-x
 
L 
 
was more dispersed. Importantly,
however, the fraction containing the vast majority of
Apaf-1 (fraction 5) had very little Bcl-x
 
L
 
 (
 
,
 
1% by densito-
metric measurements) and no detectable Bcl-2. Thus, even
in the absence of detergent, most Apaf-1 was not associ-
ated with these pro-survival molecules. Nor was Apaf-1
detectable in either nuclei or mitochondria purified from
HeLa or Jurkat cells by Dounce homogenization in the ab-
sence of detergent (data not shown).
Interestingly, the vast majority of procaspase-9 also sed-
imented distinctly from Apaf-1 (Fig. 4 E). The coimmuno-
precipitation of these two proteins from lysates of cells in
which either or both are overexpressed (Hu et al., 1998;
Pan et al., 1998; Moriishi et al., 1999) must be produced by
overexpression because we detected no association of the
endogenous proteins (Fig. 4 F), even though the antibod-
ies used can precipitate the complexes of the overex-
pressed proteins (Moriishi et al., 1999). Hence, as also con-
cluded by others (Rodriguez and Lazebnik, 1999; Zou et
al., 1999), Apaf-1, and procaspase-9 do not associate inside
healthy cells.
 
Apaf-1 Localization Was Unaltered by Elevated Bcl-2
 
Although we found no evidence that endogenous Bcl-
2–like molecules sequester Apaf-1 to cytoplasmic mem-
branes (Figs. 1–3 and data not shown), it seemed possible
that raising the Bcl-2 concentration might cause Apaf-1 to
translocate, as overexpressed CED-9 did with CED-4
(James et al., 1997; Wu et al., 1997b). Therefore, we ana-
lyzed HeLa cells that stably overexpress Bcl-2 or Bcl-x
 
L
 
and were thereby rendered refractory to death induced by
UV irradiation, staurosporine, or etoposide (data not
shown). The Apaf-1 staining pattern in these cells was in-
distinguishable from that of the parental HeLa cells, and
was almost entirely distinct from that of Bcl-2 (Fig. 5 A)
and largely distinct from that of Bcl-x
 
L
 
 (Fig. 5 B). In con-
trast to the pan-cytoplasmic distribution of Apaf-1, Bcl-2
was predominantly perinuclear, with smaller amounts on
the mitochondria (Fig. 5 A), and Bcl-x
 
L
 
 was mainly mito-
chondrial (Fig. 5, B and C). Moreover, in fractionated ly-
sates of HeLa cells overexpressing either Bcl-2 or Bcl-x
 
L
 
,
Apaf-1 remained cytosolic (Fig. 5, right panels). Further-
more, even an overexpression of Apaf-1 in HeLa cells that
overexpress Bcl-2 or Bcl-x
 
L
 
 did not lead to its colocaliza-
tion with the pro-survival proteins (data not shown).
 
Apaf-1 Localization Was Unchanged by
Apoptotic Stimuli
 
The recruitment of the cytosolic adapter FADD/MORT1
to the plasma membrane upon ligation of a death receptor
leads to the formation of a multimeric complex that pro-
motes the activation of caspase-8 (Kischkel et al., 1995;
Ashkenazi and Dixit, 1998), most likely by the induced
proximity of zymogen molecules (Salvesen and Dixit,
1999). By analogy, Apaf-1 might also shift location as apop-
tosis is initiated. Hence, we examined Apaf-1 in HeLa
cells exposed to cell death stimuli that require its function,
namely UV irradiation and etoposide (VP-16; Cecconi et
al., 1998; Yoshida et al., 1998). These stimuli induced cyto-
chrome
 
 c
 
 release into the cytosol and procaspase-9 cleav-
age (Fig. 6, compare A with B and C), accompanied by some
Figure 4. Biochemical evidence that Apaf-1 is a cytosolic mono-
meric protein that is not associated with Bcl-2, Bcl-xL, or pro-
caspase-9. (A) HeLa cells lysed in 0.025% digitonin were frac-
tionated into soluble (s) and insoluble (p) fractions, equivalent
aliquots of each were resolved by SDS-PAGE, and the filter was
probed with antibodies to Apaf-1, Bcl-x, Bcl-2, VDAC/porin
(marker for mitochondrial membranes) and calnexin (marker for
ER). Lysates from MCF-7 (B), Jurkat (C), or HepG2 (D) cells
were analyzed similarly. (E) Apaf-1 sedimented separately from
most of the Bcl-xL, Bcl-2, and procaspase-9 molecules. HeLa cell
lysates prepared by Dounce homogenization were centrifuged
through a 50–10% sucrose gradient, and nine equivalent fractions
(collected and numbered from the bottom) were resolved elec-
trophoretically and immunoblotted with antibodies to the indi-
cated proteins. The arrow marks the mobility of the 232-kD cata-
lase marker. (F) Endogenous Apaf-1 and procaspase-9 do not
coprecipitate. Lysate from 106 HeLa cells (lane 1) and anti–pro-
caspase-9 and anti–Apaf-1 immunoprecipitates from 5 3 106
HeLa cells were blotted with anti–Apaf-1 2E12 or anti–caspase-9
antibodies. HC marks immunoglobulin heavy chains from the im-
munoprecipitate. Data shown are representative of three or more
independent experiments. 
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clustering of mitochondria near the nucleus, as has been
previously noted (De Vos et al., 1998; Li et al., 1998; Degli
Esposti et al., 1999). Nevertheless, Apaf-1 remained en-
tirely cytosolic, and its staining pattern was unchanged.
When overexpressed, Bcl-x
 
L 
 
efficiently inhibited cyto-
chrome
 
 c
 
 release, procaspase-9 activation, and cell death,
but it did not affect the location of Apaf-1 (Fig. 6 D). Im-
munogold EM on HepG2 cells that were induced to die by
UV irradiation also failed to reveal any shift in Apaf-1 lo-
calization, even though they clearly had assumed an apop-
totic morphology (data not shown).
Upon induction of apoptosis, Bcl-2 or Bcl-x
 
L 
 
conceiv-
ably might instead translocate to cytosolic Apaf-1. How-
ever, in accord with our previous finding that Bcl-2 and
Bcl-x
 
L 
 
did not immunoprecipitate with Apaf-1 after induc-
tion of apoptosis (Moriishi et al., 1999), Bcl-2 remained in
the insoluble fraction and, as noted previously (Hsu et al.,
1997), the soluble Bcl-x
 
L 
 
molecules actually translocated
into the insoluble fraction (Fig. 6, compare A with B).
Thus, apoptotic stimuli did not provoke their association
with Apaf-1.
 
Bcl-x
 
L 
 
Precluded Formation of Larger Apaf-1 
Complexes In Vivo but Not In Vitro
 
Recent findings suggest that procaspase-9 activation in-
volves the formation of higher order Apaf-1-containing
multimers, a process which requires dATP and cyto-
chrome
 
 c
 
 (Cain et al., 1999; Saleh et al., 1999; Zou et al.,
1999). When HeLa cells were treated with UV, most of the
endogenous Apaf-1 did enter larger complexes (Fig. 7 A),
Figure 5. Endogenous Apaf-1 does not colocalize with overex-
pressed Bcl-2 or Bcl-xL. Apaf-1 localization in HeLa cells that
stably overexpress Bcl-2 (A) or Bcl-xL (B) was analyzed by con-
focal microscopy and subcellular fractionation. Apaf-1 was re-
vealed with Texas red–conjugated detection of anti–Apaf-1 2E12
or 19G9 staining (first panels), for Bcl-2 (with anti-human Bcl-
2-100) or Bcl-xL (anti–Bcl-x 7B2.5) revealed with FITC-conju-
gated. In the overlays (third panels), yellow staining indicates the
extent of colocalization. Data shown are representative of $20
cells examined. The blots (right-hand panels) show equivalent al-
iquots of soluble (s) and pellet (p) fractions from digitonin lysates
of these cells, which were probed for the indicated proteins. (C)
Colocalization of Bcl-xL with mitochondria. HeLa cells that sta-
bly overexpress Bcl-xL were analyzed by confocal microscopy af-
ter staining with MitoTracker red (first panel) and anti–Bcl-x
plus FITC-conjugated anti-mouse IgG (second panel); the im-
ages were overlaid in the third panel. Data shown are representa-
tive of at least three experiments. Bars, 10 mm.
Figure 6. The location of Apaf-1 is unchanged after apoptotic
stimuli, even when Bcl-xL is overexpressed. Apaf-1 in HeLa
(A–C) or a subline overexpressing Bcl-xL (D) was examined by
confocal microscopy (left) after staining with both anti–Apaf-1
2E12 (green) and MitoTracker red, or by subcellular fraction-
ation and blotting with antibodies to the indicated proteins
(right). HeLa cells were left untreated (A), or incubated for 6 h
after exposure to 50 J m22 UV irradiation (B), or incubated for
24 h with 100 ng ml21 etoposide (VP-16) continuously (C). The
HeLa/Bcl-xL cells were incubated for 6 h after exposure to 50 J
m22 UV irradiation (D). The proportion of dead cells at harvest
is indicated in parentheses, but all the HeLa cells die by 48 h with
these treatments. The asterisk marks the 35-kD–processed
caspase-9 fragment. The immunofluorescence images are repre-
sentative of $20 cells examined. Bars, 10 mm.The Journal of Cell Biology, Volume 149, 2000 630
and this shift was precluded in cells that overexpress Bcl-
xL (Fig. 7 B) or Bcl-2 (data not shown). Because the pro-
survival proteins also blocked cytochrome c release (Fig. 6
D), we tested how the addition of cytochrome c and dATP
affected endogenous Apaf-1 in extracts of healthy cells.
Addition of these cofactors caused endogenous Apaf-1 to
form larger complexes and allowed its processing of en-
dogenous procaspase-9 (Fig. 7 C). Importantly, both of
these in vitro changes were equivalent in extracts of cells
that overexpressed Bcl-2 or Bcl-xL (Fig. 7 D and data not
shown). These results suggest that Bcl-2 and Bcl-xL do not
directly prevent Apaf-1 activation, but instead function by
controlling events upstream of cytochrome c release.
Discussion
If pro-survival Bcl-2 family members prevented the activa-
tion of caspases by sequestering the caspase-activator
Apaf-1, as proposed in the apoptosome model (Hengart-
ner, 1998), most if not all of the Apaf-1 molecules should
localize with them on the organelles where they reside.
Two novel mAbs, which recognize epitopes present on all
known isoforms of Apaf-1 (Hu et al., 1999; Zou et al.,
1999), allowed us to test this prediction with endogenous
Apaf-1, thereby avoiding potential artifacts caused by its
overexpression.
We found no convincing evidence for colocalization of
Apaf-1 with either Bcl-2 or Bcl-xL. On subcellular frac-
tionation, in the presence or absence of detergent, Apaf-1
behaved almost entirely as a soluble monomeric protein,
and very little comigrated with Bcl-2 or Bcl-xL on sucrose
gradients (Fig. 4 E). Apaf-1 is cytosolic (Figs. 1–4; Zhivo-
tovsky et al., 1999) and remained so even when Bcl-2 or
Bcl-xL were overexpressed (Fig. 5) or after induction of
apoptosis (Fig. 6; Zhivotovsky et al., 1999). In confocal mi-
croscopy, endogenous Apaf-1 gave a cytoplasmic pattern
distinct from the nuclear membrane, mitochondria, and
the ER sites where Bcl-2 and Bcl-xL reside (Figs. 1–5).
This pattern of Apaf-1 staining was observed in diverse
cell types and with two antibodies that recognize different
regions within Apaf-1. Our fractionation studies suggested
that Apaf-1 is not bound within any intracellular mem-
brane, and immunogold electron microscopy confirmed
that Apaf-1 is dispersed over the cytoplasm and not associ-
ated with the organelles where the Bcl-2–like proteins re-
side (Fig. 3). Indeed, the EM studies ruled out any signifi-
cant association with intracytoplasmic membranes. Thus, a
combination of biochemical and imaging techniques allow
us to conclude that Apaf-1 is a cytosolic protein, although
it may associate with other regulatory proteins.
In support of our conclusion that endogenous Apaf-1
does not colocalize with Bcl-2 or Bcl-xL, we recently re-
ported that it failed to coimmunoprecipitate with any of
the six known mammalian pro-survival Bcl-2 relatives in
lysates of cells made either before or after induction of
apoptosis (Moriishi et al., 1999). Thus, in contrast to the
interaction and colocalization demonstrated for CED-9 and
CED-4 by comparable experimental approaches (Chin-
naiyan et al., 1997; James, 1997; Spector et al., 1997; Wu et
al., 1997b), we have not detected analogous complexes be-
tween mammalian Bcl-2–like proteins and Apaf-1, even in
the fraction where Apaf-1 and Bcl-xL cosediment (data
not shown). Collectively, our results strongly suggest that,
contrary to the apoptosome model, the Bcl-2–like proteins
do not control Apaf-1 activity by direct sequestration, but
instead must govern its activation indirectly.
How might this be achieved? On induction of cell death
(Fig. 6), Apaf-1 did not appear to translocate, as do the
adapter FADD/MORT1 (Kischkel et al., 1995) and many
of the pro-apoptotic members of the Bcl-2 family (Zha et
al., 1996; del Peso et al., 1997; Hsu et al., 1997; Wolter et
al., 1997; Puthalakath et al., 1999). Apaf-1, which is free
from procaspase-9 in healthy cells (Fig. 4, E and F; Rod-
riguez and Lazebnik, 1999; Zou et al., 1999), on induction
of cell death became part of larger complexes in vivo (Fig.
7 A; Zou et al., 1999). These complexes, which may reflect
Figure 7. Apoptotic stimuli induce formation of larger Apaf-1
complexes in vivo and in vitro. (A) Larger Apaf-1–containing
complexes formed in vivo in UV-irradiated cells. Lysates, pre-
pared by Dounce homogenization in the presence of 50 mM
zVAD.fmk, from healthy HeLa cells (top) or 6 h after UV irradi-
ation (100 J m22, bottom) were fractionated on 10–50% sucrose
gradients, and the blots were probed with anti–Apaf-1 2E12. P
represents pellet, which would include large protein aggregates
as well as organelles. (B) Bcl-xL blocks formation of larger Apaf-
1–containing complexes. Lysates from HeLa/Bcl-xL cells were
prepared and analyzed as in A. In in vitro studies (C and D), ad-
dition of dATP and cytochrome c induced formation of larger
Apaf-1–containing complexes in extracts of either parental HeLa
cells (C) or a subline overexpressing Bcl-xL (D). Equivalent
amounts of the lysates were resolved on sucrose gradients after
incubation in the absence (top) or presence of dATP/cytochrome
c (bottom). Cleavage of pro-caspase-9 in the absence (C) or pres-
ence of Bcl-xL overexpression (D) was detected by probing
equivalent lysates with an antibody to caspase-9 (right panels).
Markers included the 232-kD catalase (closed arrows) and the
158-kD aldolase (open arrows).Hausmann et al. Apaf-1 Does Not Colocalize with Bcl-2 631
self-association and/or binding to other molecules, pre-
sumably lead to the activation of procaspase-9 (Li et al.,
1997; Srinivasula et al., 1998), probably by the generation
of an active holoenzyme (Rodriguez and Lazebnik, 1999).
The formation of larger Apaf-1–containing complexes in
apoptotic cells could be readily recapitulated in vitro by
addition of cytochrome c and dATP to lysates of healthy
cells (Fig. 7 C), which is consistent with other recent evi-
dence that these Apaf-1 cofactors participate in the forma-
tion of such complexes (Cain et al., 1999; Saleh et al., 1999;
Zou et al., 1999).
Because overexpressed Bcl-xL or Bcl-2 inhibited both
the cytochrome c release and the formation of larger
Apaf-1 complexes in vivo after cytotoxic treatment (Figs. 6
D and 7 B), but did not prevent its aggregation after addi-
tion of exogenous dATP and cytochrome c (Fig. 7 D), their
function may include maintenance of mitochondrial integ-
rity to prevent Apaf-1 activation (Kluck et al., 1997; Yang
et al., 1997; Bossy-Wetzel et al., 1998), as in model 1 of Fig.
8. For example, Bcl-2 might control the release of cyto-
chrome c and other pro-apoptotic molecules by regulating
the integrity of the mitochondrial membrane (Vander
Heiden et al., 1997) or by its association with mitochon-
drial pores (Marzo et al., 1998; Shimizu et al., 1999). Such
a model does not preclude the possibility that Bcl-2 per-
forms more than one function (Swiss army knife model;
Hengartner, 1998), as suggested by its multiple reported
biological activities and binding partners (Kroemer, 1997;
Reed, 1997).
Nevertheless, given the evolutionary conservation of
cell death pathways, a variation of the apoptosome model
remains an attractive possibility. Although our data
strongly argue against an apoptosome containing Bcl-2 or
Bcl-xL together with Apaf-1 (Moriishi et al., 1999; and this
paper), Bcl-2 may instead function by direct interaction
with an as-yet-unidentified mammalian CED-4 homo-
logue, adapter X in model 2, that acts upstream of Apaf-1
(Fig. 8). The possibility that such a CED-4 homologue
remains to be found is suggested by the observations
that mammalian Apaf-1 and its Drosophila counterpart
DARK (Rodriguez et al., 1999) contain a COOH-terminal
regulatory region absent from the C. elegans protein, and
that the latter does not require cytochrome c as a cofactor
(Yang et al., 1998). In this model, the authentic mamma-
lian CED-4 regulates an initiator procaspase (Y) whose
activation results in the release of cytochrome c and other
apoptogenic factors from organelles. Apaf-1 and pro-
caspase-9 might serve primarily to amplify the apoptotic
pathway downstream of the step regulated by Bcl-2. The
ability of Bcl-2 to regulate a membrane-bound procaspase
(Krebs et al., 1999) would be consistent with such a model.
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